AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth

ملخص مفصل

AbbVie has delivered a strong share price run in recent years, and with the stock around US$295 the key question is how firmly its current market value rests on the cash it can…

AbbVie has delivered a strong share price run in recent years, and with the stock around US$295 the key question is how firmly its current market value rests on the cash it can generate over time.

The stock's next move may depend on whether those cash flows, when valued using a Discounted Cash Flow (DCF) approach, are sufficient to support where AbbVie trades today.

If you want more context around AbbVie's cash flow story, it can help to compare it with other businesses screened using similar valuation and quality criteria such as 32 high quality undervalued stocks.

The Discounted Cash Flow (DCF) model here uses AbbVie's future free cash flows to estimate what the shares could be worth today. On this approach, the latest twelve month free cash flow sits at about $18.9b, with analyst projections pointing to growing cash generation through the next decade rather than a shrinking base.

Those forecasts build in rising free cash flow into the early 2030s, then taper into more modest growth, which is typical for a large, mature pharmaceutical group. Because the projections already assume continued expansion in therapies like immunology and neuroscience, the model still places AbbVie's intrinsic value substantially above the current share price of $295.03. The recent update that AbbVie defied its Humira patent cliff with growth from newer drugs helps explain why the DCF can support richer cash flow assumptions than a simple backward looking view might suggest. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.

Simply Wall St Narratives pick up where the AbbVie valuation puzzle leaves off and spell out the specific paths on growth, margins and earnings that would need to hold for the stock to look meaningfully higher or lower than today's price.

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

Before you stop at the…

This…

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.